2024.06.07 14:55 Heavyweightszz Hello
DM me I’m your savior submitted by Heavyweightszz to AdderallAdvocatez [link] [comments] FYI real farmapram does not suck. Btw check dates of all my scripts. Addys 30s 10s Xanax 2mg Vyvanse 40mg Roxycodone 5mg |
2024.06.05 05:38 primerr69 Some one posted there cancer drugs. 400 a pill. I’m sitting on a gold mine.
submitted by primerr69 to interestingasfuck [link] [comments] |
2024.06.02 13:06 HotSarcasm $TEVA: Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
2024.06.01 01:54 Intrepid_Night7829 Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.
Idk why the guy who posted the vid said looks like someone used inspect element. Or whoever added that writing that was just the screenshot I got sent the screenshot of the vid so I didn't add that writing. Idek what that means lmao. But I sent them to a lab and got xylazine test strips, both came back positive. submitted by Intrepid_Night7829 to NovelOpioids [link] [comments] Just be careful, idk who the seller is apart from they sell in bulk and sell alot of them in the UK. My friend is trying to track whoever it is down. And I'm trying to spread awareness because alot of people are buying them. Please be careful. About a month or two ago my friend brought 100 boxes of what appeared to be accord codeine phosphates. He had the intention to make lean out of them. I'm a regular user of codeine and Dhc as I use them for pain, I was prescribed codeine for a long time before starting DHC and used to regularly get boxes off someone who goes to the same pharmacy as me as they don't need them and I use them for pain. My friend said he had got a good deal and sold me a box before selling to anyone on a larger scale. Me and him both tried them. I noticed the boxes were a bit off, and the tablets were huge in comparison to usual codeine phosphates. However the expiry date was this year, so we thought maybe they were just old and accord had changed the size and look of the pills. I also noticed they dissolved very quickly. I tried my normal dose, which is usually around 10-14(maximum metabolized amount you can take at once). I'm on DHC which is 2× as potent so 14×30mg codeine phosphates normally doesn't do much but stop Abit of pain and give me a histamine response. I thought they looked off but I was in withdrawal so I just didn't think and wanted to be out of it. However I noticed I was having weird hallucinations and felt incredibly weird and sleepy. I ended up blacking out, so I knew they were off and immediately told him. But I had not slept in 24hrs so I said it could be that. But just Incase I sent them to a lab to get tested and got xylazine test strips. And it turns out they were just xylazine and nothing else. I was dumb stuck, I didn't think tranq would be in the UK, let alone in codeine which is normally easily available. They are in strips, the strips look 100% perfect apart from the pill sizes. No imperfections. And they came in boxes that were sealed. I sent 2 boxes to get tested and every pill was the same result. The vendor, who is in the UK is apparently an old guy who gets a lot of prescriptions and had an 'old supply'. He's selling these boxes in bulk, to loads of people. And the normal person who does not use often would not be able to tell unless you are a regular user of codeine. You can see my results on wedinos type in reference code : W051815. Before I even checked my results my friend saw someone made a video sharing my results, same reference code, same postcode and same date I put on the form. Whoever that is who made that vid, thankyou. I'm now trying to spread awareness to people. I never thought it would get to the point where we have fake codeine in the UK, fakes in strips that look legitimately pharma unless you know what the pills from accord exactly look like. So if you get any accord codeine, that has a C imprint on one side and a 30 imprint on the other be careful. A simple test would be to place a pill in legit like 2ml of water and it'll instantly dissolve. So please, make sure your getting real codeine. You can check for reference what they should look like. You even better be careful buying lean. As someone unknowingly could have brought them to make lean with. If you buy homebrew in the UK and it makes you feel off, or incredibly sleepy, or Abit like ketamine but with an awful feeling be careful. Buy test strips. Luckily I can get real codeine from a person who goes to the same pharmacy as me. But others might not be so lucky. Not all codeine or homebrew is fake. My friend has chucked his supply, took the loss and is now only getting from trustworthy sources just for a more expensive price. There is still legitimate codeine out there, but please just be careful, especially with accords. My friend just resulted to buying Tevas and BP, and all have been legitimate and also tested. So not everything is fake but be weary. Unfortunately there are people who make fake stuff that looks real for a quick buck. We've been trying to track down the supplier because he's selling loads and loads of these in the UK. If anyone wants to PM for pics of the fakes to check thats ok with me. |
2024.06.01 01:54 Intrepid_Night7829 Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.
Idk why the guy who posted the vid said looks like someone used inspect element. Or whoever added that writing that was just the screenshot I got sent the screenshot of the vid so I didn't add that writing. Idek what that means lmao. But I sent them to a lab and got xylazine test strips, both came back positive. submitted by Intrepid_Night7829 to NovelOpioids [link] [comments] Just be careful, idk who the seller is apart from they sell in bulk and sell alot of them in the UK. My friend is trying to track whoever it is down. And I'm trying to spread awareness because alot of people are buying them. Please be careful. About a month or two ago my friend brought 100 boxes of what appeared to be accord codeine phosphates. He had the intention to make lean out of them. I'm a regular user of codeine and Dhc as I use them for pain, I was prescribed codeine for a long time before starting DHC and used to regularly get boxes off someone who goes to the same pharmacy as me as they don't need them and I use them for pain. My friend said he had got a good deal and sold me a box before selling to anyone on a larger scale. Me and him both tried them. I noticed the boxes were a bit off, and the tablets were huge in comparison to usual codeine phosphates. However the expiry date was this year, so we thought maybe they were just old and accord had changed the size and look of the pills. I also noticed they dissolved very quickly. I tried my normal dose, which is usually around 10-14(maximum metabolized amount you can take at once). I'm on DHC which is 2× as potent so 14×30mg codeine phosphates normally doesn't do much but stop Abit of pain and give me a histamine response. I thought they looked off but I was in withdrawal so I just didn't think and wanted to be out of it. However I noticed I was having weird hallucinations and felt incredibly weird and sleepy. I ended up blacking out, so I knew they were off and immediately told him. But I had not slept in 24hrs so I said it could be that. But just Incase I sent them to a lab to get tested and got xylazine test strips. And it turns out they were just xylazine and nothing else. I was dumb stuck, I didn't think tranq would be in the UK, let alone in codeine which is normally easily available. They are in strips, the strips look 100% perfect apart from the pill sizes. No imperfections. And they came in boxes that were sealed. I sent 2 boxes to get tested and every pill was the same result. The vendor, who is in the UK is apparently an old guy who gets a lot of prescriptions and had an 'old supply'. He's selling these boxes in bulk, to loads of people. And the normal person who does not use often would not be able to tell unless you are a regular user of codeine. You can see my results on wedinos type in reference code : W051815. Before I even checked my results my friend saw someone made a video sharing my results, same reference code, same postcode and same date I put on the form. Whoever that is who made that vid, thankyou. I'm now trying to spread awareness to people. I never thought it would get to the point where we have fake codeine in the UK, fakes in strips that look legitimately pharma unless you know what the pills from accord exactly look like. So if you get any accord codeine, that has a C imprint on one side and a 30 imprint on the other be careful. A simple test would be to place a pill in legit like 2ml of water and it'll instantly dissolve. So please, make sure your getting real codeine. You can check for reference what they should look like. You even better be careful buying lean. As someone unknowingly could have brought them to make lean with. If you buy homebrew in the UK and it makes you feel off, or incredibly sleepy, or Abit like ketamine but with an awful feeling be careful. Buy test strips. Luckily I can get real codeine from a person who goes to the same pharmacy as me. But others might not be so lucky. Not all codeine or homebrew is fake. My friend has chucked his supply, took the loss and is now only getting from trustworthy sources just for a more expensive price. There is still legitimate codeine out there, but please just be careful, especially with accords. My friend just resulted to buying Tevas and BP, and all have been legitimate and also tested. So not everything is fake but be weary. Unfortunately there are people who make fake stuff that looks real for a quick buck. We've been trying to track down the supplier because he's selling loads and loads of these in the UK. If anyone wants to PM for pics of the fakes to check thats ok with me. |
2024.05.31 22:25 kokopelleee Grand Canyon Rim-to-Rim-to-Rim, May 2024
2024.05.31 01:40 Panda_MAN420_918 Weekly script of 21-5mg and 21-2mg valium
submitted by Panda_MAN420_918 to benzodiazeland [link] [comments] |
2024.05.30 12:47 HotSarcasm $TEVA: Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
2024.05.23 11:16 Pizdokleszczu Meds shortage? Teva brand Dexamfetamines
2024.05.14 03:23 TeddyBearOverlord Anyone else get weird side effects from generic Wellbutrin?
2024.05.10 06:12 Otherwise_Error3325 All Script.... All Mine!
submitted by Otherwise_Error3325 to bud_n_pill_lovers [link] [comments] |
2024.05.10 00:43 Netdocs Diazepam 10mg 🚀💊
submitted by Netdocs to esctacy_cloud [link] [comments] |
2024.05.09 23:46 Waltersprite_ TEVA FROM FARM TO FORK
I use teva materials, and make teva pints… submitted by Waltersprite_ to lean365 [link] [comments] Never once claimed them to be legit, however I do claim them to be honest, clean and pack a punch!!!! WALTERSPRITE the king of brew…. If you didn’t already know, soon you will!! |
2024.05.09 23:17 RestaurantOk3089 alright here
submitted by RestaurantOk3089 to benzodiazeland [link] [comments] |
2024.05.08 19:35 Intelligent-Mud9251 Better than Valium?
U tell me submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments] |
2024.05.08 13:15 HotSarcasm $TEVA: Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Mr. Richard Francis, Teva's President and CEO, said, "In 2024 Teva is off to a good start, with global revenues of $3.8 billion showing growth of 5% in local currency terms compared to Q1 2023, fueled by robust growth in our generics business across all regions, and continued growth of our innovative brands AUSTEDO and AJOVY." Mr. Francis continued, “As we mark the first anniversary of our Pivot to Growth Strategy, I am proud of the significant strides we have been making in realizing the goals and milestones we set out to achieve on our journey to growth, including the progression of our innovative pipeline and growth drivers, as well as the recent FDA approvals of SIMLANDI and SELARSDI, the biosimilars to Humira® and Stelara®, respectively, and the positive Phase 3 efficacy results for olanzapine Once-Monthly LAI announced this morning. The study met its primary endpoint, demonstrating a well-tolerated effective long-acting treatment option for schizophrenia, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date. As we continue to accelerate our growth progress, we reaffirm our financial guidance for 2024." Pivot to Growth Strategy In May 2023, we introduced our “Pivot to Growth” strategy, which is based on four key pillars: (i) delivering on our growth engines, mainly AUSTEDO, AJOVY, UZEDY® and our late-stage pipeline of biosimilars; (ii) stepping up innovation through delivering on our late-stage innovative pipeline assets as well as building up our early-stage pipeline organically and potentially through business development activities; (iii) sustaining our generics medicines powerhouse with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint; and (iv) focusing our business by optimizing our portfolio and global manufacturing footprint to enable strategic capital deployment to accelerate our near and long-term growth engines and reorganizing certain of our business units to a more optimal structure, while also reorganizing key business units to enhance operational efficiency. First Quarter 2024 Consolidated Results The data presented in this press release with respect to operating income (loss), income (loss) before income taxes, income taxes (benefit), net income (loss) attributable to Teva and earnings (loss) per share for prior period has been revised to reflect a revision in relation to a contingent consideration and related expenses. For additional information, see note 1b to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 and note 1c to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2024. Revenues in the first quarter of 2024 were $3,819 million, an increase of 4% in U.S. dollars or 5% in local currency terms compared to the first quarter of 2023. This increase was mainly due to higher revenues from generic products in all our segments, from AUSTEDO, as well as from AJOVY in our Europe and International Markets segments, partially offset by lower revenues from COPAXONE®, and from Anda, our distribution business in the U.S. Exchange rate movements during the first quarter of 2024, net of hedging effects, negatively impacted overall revenues by $39 million, compared to the first quarter of 2023. Exchange rate movements during the first quarter of 2024, including hedging effects, negatively impacted our operating income and non-GAAP operating income each by $11 million compared to the first quarter of 2023. Gross profit in the first quarter of 2024 was $1,771 million, an increase of 12% compared to $1,582 million in the first quarter of 2023. Gross profit margin was 46.4% in the first quarter of 2024, compared to 43.2% in the first quarter of 2023. Non-GAAP gross profit was $1,963 million in the first quarter of 2024, an increase of 9% compared to $1,796 million in the first quarter of 2023. Non-GAAP gross profit margin was 51.4% in the first quarter of 2024, compared to 49.1% in the first quarter of 2023. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products as well as a decrease in our operational costs. Research and Development (R&D) expenses, net in the first quarter of 2024 were $242 million, an increase of 4% compared to $234 million in the first quarter of 2023, as we continued to execute on our Pivot to Growth Strategy. Our higher R&D expenses, net in the first quarter of 2024, compared to the first quarter of 2023, were mainly due to an increase related to our late-stage innovative pipeline in neuroscience (mainly neuropsychiatry) and in immunology and immuno-oncology. Our R&D expenses, net in the first quarter of 2024 were also impacted by reimbursements from our strategic partnerships. Selling and Marketing (S&M) expenses in the first quarter of 2024 were $608 million, an increase of 11% compared to the first quarter of 2023 to support our Pivot to Growth strategy, mainly related to commercial activities for AUSTEDO and UZEDY in the U.S. General and Administrative (G&A) expenses in the first quarter of 2024 were $278 million, a decrease of 6% compared to the first quarter of 2023, mainly due to lower litigation fees in the first quarter of 2024. Operating loss in the first quarter of 2024 was $218 million, compared to an operating loss of $13 million in the first quarter of 2023. Operating loss as a percentage of revenues was 5.7% in the first quarter of 2024, compared to an operating loss as a percentage of revenues of 0.4% in the first quarter of 2023. The higher operating loss in the first quarter of 2024 was mainly due to higher other assets impairments, restructuring costs and other items, as well as higher S&M expenses in the first quarter of 2024, partially offset by higher gross profit, lower legal settlements and loss contingencies and lower intangible asset impairments in the first quarter of 2024. Non-GAAP operating income in the first quarter of 2024 was $892 million representing a non-GAAP operating margin of 23.4% compared to non-GAAP operating income of $785 million representing a non-GAAP operating margin of 21.4% in the first quarter of 2023. The increase in non-GAAP operating margin in the first quarter of 2024 was mainly impacted by an increase in non-GAAP gross profit margin, partially offset by higher S&M expenses as a percentage of revenues. Financial expenses, net in the first quarter of 2024 were $250 million, mainly comprised of net-interest expenses of $233 million. In the first quarter of 2023, financial expenses, net were $260 million, mainly comprised of net-interest expenses of $236 million. In the first quarter of 2024, we recognized a tax benefit of $52 million, on a pre-tax loss of $467 million. In the first quarter of 2023, we recognized a tax benefit of $19 million, on a pre-tax loss of $272 million. Our tax rate for the first quarter of 2024 was mainly affected by deferred tax benefits resulting from Intellectual Property ("IP")- related integration plans. Such integration plans have been adopted, among others, in an effort of addressing the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax, commencing in 2024. Tax rate in the first quarter of 2024 was 11.1%, compared to 7.1% in the first quarter of 2023. Our tax rate for the first quarter of 2024 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans. Non-GAAP tax rate in the first quarter of 2024 was 15.0%, compared to 15.5% in the first quarter of 2023. Our non-GAAP tax rate in the first quarter of 2024 was mainly affected by deferred tax benefits resulting from IP-related integration plans, the generation of profits in various jurisdictions with different tax rates, tax benefits in Israel and other countries, as well as infrequent or non-recurring items. Our non-GAAP tax rate in the first quarter of 2023 was mainly affected by the geographic mix of earnings and interest expense disallowances. We expect our annual non-GAAP tax rate for 2024 to be between 14%-17%, higher than our non-GAAP tax rate for 2023, which was 13%, mainly due to a reduced net tax benefit related to deferred tax resulting from IP-related integration plans in 2024 compared to 2023. Net loss attributable to Teva and loss per share in the first quarter of 2024 were $139 million and $0.12, respectively, compared to net loss attributable to Teva and loss per share of $220 million and $0.20, respectively, in the first quarter of 2023. The lower net loss in the first quarter of 2024 was mainly due to higher net loss attributable to non-controlling interests, higher gross profit and lower legal settlements and loss contingencies, partially offset by higher other asset impairments, restructuring and other items, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the first quarter of 2024 were $548 million and $0.48, respectively, compared to $457 million and $0.40, respectively, in the first quarter of 2023. Net loss attributable to non-controlling interests was $280 million in the first quarter of 2024, compared to a net loss attributable to non-controlling interests of $33 million in the first quarter of 2023. The higher net loss in the first quarter of 2024 was mainly due to higher impairments of tangible assets largely related to the classification of a business in our International Markets segment as held for sale. Adjusted EBITDA was $1,005 million in the first quarter of 2024, an increase of 12% compared to $899 million in the first quarter of 2023. As of March 31, 2024 and 2023, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,167 million and 1,158 million, respectively. Non-GAAP information: net non-GAAP adjustments in the first quarter of 2024 were $688 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the first quarter of 2024 were adjusted to exclude the following items:
For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP. Cash flow used in operating activities during the first quarter of 2024 was $124 million, compared to $145 million of cash flow used in operating activities in the first quarter of 2023. The lower cash flow used in operating activities in the first quarter of 2024 resulted mainly from higher profit in our Europe segment, partially offset by changes in certain working capital items, including a negative impact from accounts payables. During the first quarter of 2024, we generated free cash flow of $32 million, which we define as comprising $124 million in cash flow used in operating activities, $295 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program), partially offset by $124 million in cash used for capital investment and $15 million in cash used for acquisition of businesses, net of cash acquired. During the first quarter of 2023, we generated free cash flow of $41 million, which we define as comprising $145 million in cash flow used in operating activities, $323 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $2 million in proceeds from divestitures of businesses and other assets, partially offset by $139 million in cash used for capital investment. As of March 31, 2024, our debt was $19,643 million, compared to $19,833 million as of December 31, 2023. This decrease was mainly due to $193 million of exchange rate fluctuations. The portion of total debt classified as short-term as of March 31, 2024 was 16% compared to 8% as of December 31, 2023. Our average debt maturity was approximately 5.7 years as of March 31, 2024, compared to 6.0 years as of December 31, 2023. On May 3, 2024, the terms of our revolving credit facility ("RCF") were amended to update the Company’s maximum permitted leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company’s leverage ratio shall not exceed (i) 4.00x in 2024, 2025 and in the first quarter of 2026, (ii) 3.75x in the second, third and fourth quarters of 2026, and (iii) 3.50x in the first quarter of 2027 and onwards. The RCF permits the Company to increase the maximum leverage ratio if it consummates or commences certain material transactions. Segment Results for the first Quarter of 2024 United States Segment As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing January 1, 2024, Canada is reported as part of our International Markets segment and the segment previously known as our “North America” segment is now referred to as our “United States” segment. Prior period amounts were recast to reflect this change. The following table presents revenues, expenses and profit for our United States segment for the three months ended March 31, 2024 and 2023: https://preview.redd.it/0tglw4vbr6zc1.png?width=1652&format=png&auto=webp&s=f40a89b74bfb135517ac47f0b4a812d86d99aebf Revenues from our United States segment in the first quarter of 2024 were $1,725 million, an increase of $48 million, or 3%, compared to the first quarter of 2023. This increase was mainly due to higher revenues from AUSTEDO, and higher revenues from generic products, partially offset by lower revenues from certain innovative products, primarily COPAXONE and BENDEKA®and TREANDA®, as well as from Anda, our distribution business. Revenues by Major Products and Activities The following table presents revenues for our United States segment by major products and activities for the three months ended March 31, 2024 and 2023: https://preview.redd.it/9ibpylwfr6zc1.png?width=1650&format=png&auto=webp&s=79e221478e8607ad46f8fe3f80dd5f23215764ab * Other revenues in the first quarter of 2023 were higher compared to the first quarter of 2024, mainly due to a reduction in estimated liabilities in connection with ProAir® HFA during the first quarter of 2023 following its discontinuation. Generic products revenues in our United States segment (including biosimilars) in the first quarter of 2024 were $808 million, an increase of 8% compared to the first quarter of 2023, mainly due to revenues from lenalidomide capsules (the generic version of Revlimid®), partially offset by increased competition to other generic products. In the first quarter of 2024, our total prescriptions were approximately 314 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions, compared to approximately 312 million (based on trailing twelve months), representing 8.3% of total U.S. generic prescriptions in the first quarter of 2023, all according to IQVIA data. On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. In June 2023, Alvotech and Teva reached a settlement and license agreement with Johnson & Johnson, granting a licensed entry date in the U.S. no later than February 21, 2025. AJOVY revenues in our United States segment in the first quarter of 2024 were $45 million, flat compared to the first quarter of 2023. In the first quarter of 2024, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 27.4% compared to 24.5% in the first quarter of 2023. AUSTEDO revenues in our United States segment in the first quarter of 2024 increased by 67%, to $282 million, compared to $170 million in the first quarter of 2023, mainly due to growth in volume including the launch of AUSTEDO XR in May 2023, as well as expanded access for patients and increased investment to support higher demand. AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023, and became commercially available in the U.S. in May 2023. AUSTEDO XR is a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by ten Orange Book patents expiring between 2031 and 2041. UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is protected by nine Orange Book patents expiring between 2025 and 2033. We are moving forward with plans to launch UZEDY in other countries around the world. BENDEKA and TREANDA combined revenues in our United States segment in the first quarter of 2024 decreased by 26% to $46 million, compared to the first quarter of 2023, mainly due to generic bendamustine products entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022. COPAXONE revenues in our United States segment in the first quarter of 2024 decreased by 58% to $30 million, compared to the first quarter of 2023, mainly due to generic competition and a decrease in glatiramer acetate market share due to availability of alternative therapies. COPAXONE revenues in the first quarter of 2024 were also negatively impacted by an increase in sales allowance due to a non-recurring item. Anda revenues from third-party products in our United States segment in the first quarter of 2024 decreased by 10% to $381 million, compared to $424 million in the first quarter of 2023, mainly due to lower demand from seasonal and other market conditions. Anda, our distribution business in the United States, distributes generic and innovative medicines and OTC pharmaceutical products from Teva and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States. United States Gross Profit Gross profit from our United States segment in the first quarter of 2024 was $858 million, an increase of 9% compared to $789 million in the first quarter of 2023. Gross profit margin for our United States segment in the first quarter of 2024 increased to 49.8%, compared to 47.0% in the first quarter of 2023. This increase was mainly due to a favorable mix of products primarily driven by an increase in revenues from AUSTEDO and lenalidomide capsules (the generic version of Revlimid®), as well as a decrease in our operational costs. United States Profit Profit from our United States segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our United States segment in the first quarter of 2024 was $350 million, an increase of 4% compared to $338 million in the first quarter of 2023. This increase was mainly due to higher gross profit, partially offset by higher S&M expenses. Europe Segment Our Europe segment includes the European Union, the United Kingdom and certain other European countries. The following table presents revenues, expenses and profit for our Europe segment for the three months ended March 31, 2024 and 2023: https://preview.redd.it/m4cnaqwjr6zc1.png?width=1650&format=png&auto=webp&s=d29a29376f622215efb969c1af9fc9bdb0a1a63c Revenues from our Europe segment in the first quarter of 2024 were $1,272 million, an increase of 7%, or $88 million, compared to the first quarter of 2023. In local currency terms, revenues increased by 4% compared to the first quarter of 2023, mainly due to higher revenues from generic products and AJOVY. In the first quarter of 2024, revenues from our Europe segment were positively impacted by exchange rate fluctuations of $43 million, including hedging effects, compared to the first quarter of 2023. Revenues in the first quarter of 2024 included $8 million from a positive hedging impact, which is included in “Other” in the table below. Revenues in the first quarter of 2023 included $6 million from a negative hedging impact, which is included in “Other” in the table below. Revenues by Major Products and Activities The following table presents revenues for our Europe segment by major products and activities for the three months ended March 31, 2024 and 2023: https://preview.redd.it/sirwlizmr6zc1.png?width=1656&format=png&auto=webp&s=763b9e060eb705c6d19a11d9c8efa140615b8368 Generic products revenues (including OTC and biosimilar products) in our Europe segment in the first quarter of 2024, were $1,004 million, an increase of 8% compared to the first quarter of 2023. In local currency terms, revenues increased by 5%, mainly due to higher volumes. AJOVY revenues in our Europe segment in the first quarter of 2024 increased by 42% to $51 million, compared to $36 million in the first quarter of 2023. In local currency terms revenues increased by 40%, mainly due to growth in European countries in which AJOVY had previously been launched. COPAXONE revenues in our Europe segment in the first quarter of 2024 decreased by 4% to $57 million, compared to the first quarter of 2023. In local currency terms, revenues decreased by 5%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products and availability of alternative therapies. Respiratory products revenues in our Europe segment in the first quarter of 2024 decreased by 3% to $66 million compared to the first quarter of 2023. In local currency terms, revenues decreased by 5% compared to the first quarter of 2023, mainly due to net price reductions and lower volumes. Europe Gross Profit Gross profit from our Europe segment in the first quarter of 2024 was $738 million, an increase of 13% compared to $655 million in the first quarter of 2023. Gross profit margin for our Europe segment in the first quarter of 2024 increased to 58.0%, compared to 55.3% in the first quarter of 2023. This increase was mainly due to a favorable mix of products as well as a decrease in our operational costs. Europe Profit Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our Europe segment in the first quarter of 2024 was $423 million, an increase of 22%, compared to $345 million in the first quarter of 2023. This increase was mainly due to higher gross profit, as described above. International Markets Segment Our International Markets segment includes all countries in which we operate other than the United States and countries included in our Europe segment. As part of a recent shift in executive management responsibilities, commencing January 1, 2024, Canada is reported under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast to reflect this change. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, branded generics-oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan. The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March 31, 2024 and 2023: https://preview.redd.it/q5y53mcqr6zc1.png?width=1646&format=png&auto=webp&s=156ac05a7358272308c626694ba7c4cfac1a2db8 Revenues from our International Markets segment in the first quarter of 2024 were $597 million, an increase of 3% compared to the first quarter of 2023. In local currency terms, revenues increased by 17% compared to the first quarter of 2023, mainly due to higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition to off-patented products in Japan. In the first quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $82 million, net of hedging effects, compared to the first quarter of 2023. Revenues in the first quarter of 2024 included $4 million from a positive hedging impact, compared to a minimal hedging impact in the first quarter of 2023, which are included in “Other” in the table below. Revenues by Major Products and Activities The following table presents revenues for our International Markets segment by major products and activities for the three months ended March 31, 2024 and 2023: https://preview.redd.it/89uw2u7tr6zc1.png?width=1660&format=png&auto=webp&s=037437b5ca242a624dd9514bedb61cd1cf0c61c9 Generic products revenues (including OTC products) in our International Markets segment were $477 million in the first quarter of 2024, flat compared to the first quarter of 2023. In local currency terms, revenues increased by 16% compared to the first quarter of 2023, mainly due to higher revenues in most markets, largely driven by price increases as a result of higher costs due to inflationary pressure and higher volumes, partially offset by regulatory price reductions and generic competition to off-patented products in Japan. AJOVY was launched in certain markets in our International Markets segment, including in Canada, Japan, Australia, Israel, South Korea, Brazil and others. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the first quarter of 2024 were $17 million, compared to $13 million in the first quarter of 2023. COPAXONE revenues in our International Markets segment in the first quarter of 2024 were $12 million compared to $17 million in the first quarter of 2023. AUSTEDO was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the marketing and distribution of AUSTEDO in China. We continue with additional submissions in various other markets. International Markets Gross Profit Gross profit from our International Markets segment in the first quarter of 2024 was $297 million, an increase of 4% compared to $285 million in the first quarter of 2023. Gross profit margin for our International Markets segment in the first quarter of 2024 increased to 49.7%, compared to 49.0% in the first quarter of 2023. This increase was mainly due to price increases largely as a result of inflationary pressures and a favorable mix of products, partially offset by regulatory price reductions and generic competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures. International Markets Profit Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. Profit from our International Markets segment in the first quarter of 2024 was $117 million, an increase of 8%, compared to $108 million in the first quarter of 2023. Other Activities We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above. On January 31, 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with our Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. Revenues from other activities in the first quarter of 2024 were $225 million, an increase of 3% in U.S. dollars, or 2% in local currency terms compared to the first quarter of 2023. API sales to third parties in the first quarter of 2024 were $128 million, reflecting an increase of 2% in both U.S. dollars and local currency terms, compared to the first quarter of 2023, following a reallocation of an immaterial business within our other activities, in line with our intention to divest our API business. FULL RELEASE: https://www.businesswire.com/news/home/20240508490531/en/ |
2024.05.03 02:38 Intelligent-Mud9251 Stocked
Sortes submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments] |
2024.05.03 00:14 Intelligent-Mud9251 Temazepam 20mg
Tried these for the first time and man oh man double the strength off valliums submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments] |
2024.04.30 15:10 Life123456 I cant tell what type of PREP I have
2024.04.29 23:25 No-Satisfaction-8979 These aren't pressies although one guy seems to think my gg bars are fake lol.. they aren't. Some random klonz, Xan and Flexeril here.. boutta drop up
submitted by No-Satisfaction-8979 to arethesepressies [link] [comments] |
2024.04.28 23:26 Hot_Tadpole1733 Combo mixture
submitted by Hot_Tadpole1733 to bud_n_pill_lovers [link] [comments] |
2024.04.28 06:22 ReportsStack Buccal Drug Delivery Systems Market Size, Industry Trends & Growth Analysis from 2024 to 2030